AURKB
Aurora kinase B
As of the edition of 20 October 2026, AURKB (aurora kinase B, UniProt Q96GD4) has 15 drugs tested at it and 13 companies on the list, 10 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q96GD4
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 1
- Disease areas
- Cancer; Blood and lymph; Immune system; Lungs and airways; Hormones; Digestive system; Heart and blood vessels; Pregnancy and women's health
- Registered trials of its drugs
- 56
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 7 |
| Stopped | 7 |
| Total | 15 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ibcasertib | Active | Phase 3 | none listed |
| Barasertib | Went quiet | Phase 3 | none listed |
| Tozasertib | Stopped | Phase 2 | none listed |
| Defosbarasertib | Stopped | Phase 2 | none listed |
| Ilorasertib | Stopped | Phase 2 | none listed |
| Danusertib | Went quiet | Phase 2 | none listed |
| AT-9283 | Went quiet | Phase 2 | none listed |
| BI-811283 | Went quiet | Phase 2 | none listed |
| Cenisertib | Stopped | Phase 1 | none listed |
| TAK-901 | Went quiet | Phase 1 | none listed |
| CYC-116 | Stopped | Phase 1 | none listed |
| MK-6592 | Stopped | Phase 1 | none listed |
12 of 15 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 10 |
| Engaged | 3 |
| Total on the list | 13 |
| Company | Route |
|---|---|
| AstraZeneca | Route A |
| Merck & Co. | Route A |
| Pfizer | Route A |
The other 10 companies at AURKB
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at AURKB, ranked, with the facts behind eachRequest access. Nothing is shown until you do.